Jump to content

5-MeO-MET

Add links
From Wikipedia, the free encyclopedia
5-MeO-MET
Identifiers
  • N-Ethyl-2-(5-methoxy-1H-indol-3-yl)-N-methylethan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC14H20N2O
Molar mass232.327 g·mol−1
3D model (JSmol)
  • CCN(CCc1c[nH]c2c1cc(OC)cc2)C
  • InChI=1S/C14H20N2O/c1-4-16(2)8-7-11-10-15-14-6-5-12(17-3)9-13(11)14/h5-6,9-10,15H,4,7-8H2,1-3H3
  • Key:AVECDEWGCOLCPZ-UHFFFAOYSA-N

5-MeO-MET, also known as 5-methoxy-N-methyl-N-ethyltryptamine, is a relatively rare designer drug from the tryptamine family, related to compounds such as methylethyltryptamine (MET) and 5-MeO-DMT.[1][2][3][4] It was first synthesised in the 1960s and was studied to a limited extent, with studies finding it to be more potent in animal behavioral tests than 5-MeO-DMT.[1][5][6] It was first identified on the illicit market in June 2012 in Sweden.[7] It was made illegal in Norway in 2013,[8] and is controlled under analogue provisions in numerous other jurisdictions.

See also

[edit]

References

[edit]
  1. ^ a b Brimblecombe RW, Pinder RM (1975). "Indolealkylamines and Related Compounds". Hallucinogenic Agents. Bristol: Wright-Scientechnica. pp. 98–144. ISBN 978-0-85608-011-1. OCLC 2176880. OL 4850660M. Compounds of interest which have not been tested in man include 5-methoxy-N-ethyl-N-methyltryptamine, which is more potent than the N,N-dimethyl analogue in behavioural tests in rodents (Gessner and others, 1968), [...]
  2. ^ Schifano F, Orsolini L, Papanti D, Corkery J (2017). "NPS: Medical Consequences Associated with Their Intake". Neuropharmacology of New Psychoactive Substances (NPS). Current Topics in Behavioral Neurosciences. Vol. 32. pp. 351–380. doi:10.1007/7854_2016_15. ISBN 978-3-319-52442-9. PMID 27272067.
  3. ^ Palma-Conesa ÁJ, Ventura M, Galindo L, Fonseca F, Grifell M, Quintana P, Fornís I, Gil C, Farré M, Torrens M (2017). "Something New about Something Old: A 10-Year Follow-Up on Classical and New Psychoactive Tryptamines and Results of Analysis". Journal of Psychoactive Drugs. 49 (4): 297–305. doi:10.1080/02791072.2017.1320732. PMID 28569652. S2CID 45394561.
  4. ^ Malaca S, Lo Faro AF, Tamborra A, Pichini S, Busardò FP, Huestis MA (December 2020). "Toxicology and Analysis of Psychoactive Tryptamines". International Journal of Molecular Sciences. 21 (23): 9279. doi:10.3390/ijms21239279. PMC 7730282. PMID 33291798.
  5. ^ Gessner PK, Godse DD, Krull AH, McMullan JM (March 1968). "Structure-activity relationships among 5-methoxy-n:n-dimethyltryptamine, 4-hydroxy-n:n-dimethyltryptamine (psilocin) and other substituted tryptamines". Life Sciences. 7 (5): 267–77. doi:10.1016/0024-3205(68)90200-2. PMID 5641719.
  6. ^ Glennon RA, Gessner PK (April 1979). "Serotonin receptor binding affinities of tryptamine analogues". Journal of Medicinal Chemistry. 22 (4): 428–32. doi:10.1021/jm00190a014. PMID 430481.
  7. ^ "EMCDDA–Europol 2012 Annual Report on the implementation of Council Decision 2005/387/JHA" (PDF). New drugs in Europe, 2012.
  8. ^ "Forskrift om endring i forskrift om narkotika" [Regulations amending the regulations on drugs]. Lovdata (in Norwegian).
Stub icon

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=5-MeO-MET&oldid=1294508774"